K. Goh

发表

Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.

Kay Lin Goh, Z. Bonday, J. Wood, 2011, Journal of medicinal chemistry.

Arthritis and C-fms for the Treatment of Rheumatoid Sb1578, a Novel Inhibitor of Jak2, Flt3

J. Wood, B. Madan, K. Goh, 2022 .

SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis

J. Wood, A. William, B. Dymock, 2012, The Journal of Immunology.

Biosynthetic precursors of valclavam

C. Schofield, K. Goh, J. Baldwin, 1994 .

Enzymes of valclavam biosynthesis

C. Schofield, K. Goh, J. Baldwin, 1994 .

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

A. Poulsen, A. William, B. Dymock, 2011, Leukemia.

Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.

Z. Bonday, Haishan Wang, Xukun Wang, 2010, Bioorganic & medicinal chemistry letters.

PLK1 as a potential drug target in cancer therapy

Yifa Zhou, Haishan Wang, Xukun Wang, 2004 .

Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthr

J. Wood, A. Poulsen, A. William, 2012, Journal of medicinal chemistry.

Molecular Cancer Therapeutics SB 939 , a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

Z. Bonday, J. Wood, Haishan Wang, 2010 .

2-anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1.

Chang Kai Soh, Kay Lin Goh, Z. Bonday, 2012, Bioorganic & medicinal chemistry letters.

Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-

J. Wood, A. Poulsen, Meredith Williams, 2012, Journal of medicinal chemistry.

Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors.

Kay Lin Goh, Z. Bonday, A. Poulsen, 2010, Bioorganic & medicinal chemistry letters.

SIRT1 Modulating Compounds from High-Throughput Screening as Anti-Inflammatory and Insulin-Sensitizing Agents

A. Poulsen, Haishan Wang, Xukun Wang, 2006, Journal of biomolecular screening.

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

J. Wood, K. Goh, K. Ethirajulu, 2012, Blood Cancer Journal.

p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons

B. Williams, S. Haque, K. Goh, 1999, The EMBO journal.

The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin

B. Williams, K. Goh, M. deVeer, 2000, The EMBO journal.

Identification of p90, a Prominent Tyrosine-phosphorylated Protein in Fibroblast Growth Factor-stimulated Cells, as 80K-H (*)

Chia Bin Siak, Y. Tan, Y. Lim, 1996, The Journal of Biological Chemistry.

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

Z. Bonday, J. Wood, Haishan Wang, 2010, Molecular Cancer Therapeutics.

Discovery of Kinase Spectrum Selective Macrocycle

J. Wood, A. Poulsen, Meredith Williams, 2011 .

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lympho

Anders Poulsen, Stéphanie Blanchard, Harish Nagaraj, 2011, Journal of medicinal chemistry.

Structure-based design of Aurora A & B inhibitors

Eric Sun, Anders Poulsen, Anthony William, 2008, J. Comput. Aided Mol. Des..

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

J. Wood, J. Zhou, B. Madan, 2011, Blood cancer journal.

Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)

A. Poulsen, Meredith Williams, H. Nagaraj, 2012, Journal of Molecular Modeling.

Chemical Therapeutics VS-5584 , a Novel and Highly Selective PI 3 K / mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2013 .

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2012, Molecular Cancer Therapeutics.

Structure and Ligand-Based Design of mTOR and PI3-Kinase Inhibitors Leading to the Clinical Candidates VS-5584 (SB2343) and SB2602

Anders Poulsen, Stéphanie Blanchard, Angeline Lee, 2014, J. Chem. Inf. Model..

416 The oral HDAC inhibitor SB939 shows activity in in vitro and in vivo models of acute myeloid leukemia

J. Wood, Haishan Wang, K. Goh, 2010 .

Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)

Anders Poulsen, Anthony William, Stéphanie Blanchard, 2012, Journal of Computer-Aided Molecular Design.

Revised Structures for Tue 1718B (Ia) and Valclavam (Ib).

C. Schofield, K. Goh, T. Claridge, 1994 .

The biosynthesis of β-lactams

K. Goh, 1993 .

SB1518: A Potent and Orally Active JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.

Z. Bonday, J. Wood, J. Griffin, 2007 .

Thieno[3,2-d]pyrimidin-4(3H)-one derivatives as PDK1 inhibitors discovered by fragment-based screening.

Kay Lin Goh, Z. Bonday, J. Wood, 2012, Bioorganic & medicinal chemistry letters.

nonaene ( SB 1578 ) , a Potent Inhibitor of Janus Kinase 2 / Fms-LikeTyrosine Kinase-3 ( JAK 2 / FLT 3 ) for the Treatment of Rheumatoid Arthritis

Anders Poulsen, Harish Nagaraj, Evelyn Tan, 2012 .

SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis

J. Wood, A. William, B. Dymock, 2012, The Journal of Immunology.

SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer

J. Wood, Haishan Wang, S. Pettersson, 2010, Molecular Cancer Therapeutics.

Supporting Information: Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl- ethoxy)-14,19-dioxa-5,7,26-triaza- tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment o

Harish, J. Wood, Meredith Williams, 2011 .

This information is current as Arthritis and c-Fms for the Treatment of Rheumatoid SB 1578 , a Novel Inhibitor of JAK 2 , FLT 3 , Dymock and

B. Madan, K. Goh, K. Ethirajulu, 2012 .

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

U. McDermott, M. Garnett, C. Benes, 2012, Molecular Cancer Therapeutics.